We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 25,898

Pharma in brief - Federal Court recommendations on “increased proportionality in complex litigation” impact Canadian pharmaceutical patent litigation
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 3 2015

The Federal Court issued a Notice to the Parties and the Profession dated June 24, 2015 (the "Notice") containing its initial recommendations


Full Court dismisses Garford’s appeal and upholds decision that patent claims are invalid
  • Davies Collison Cave
  • Australia
  • July 2 2015

The Full Federal Court has dismissed an appeal by Garford against the decision by Yates J that claims of its patent were invalid, and that it made


Advances in design patent protection - a United States and European overview
  • Baker Botts LLP
  • European Union, USA
  • July 2 2015

Increased investment in design is positively correlated to turnover growth. It is estimated that the growth for companies that protect their designs


New guidance on diagnostic method claims
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 2 2015

On June 29, 2015, the Canadian Intellectual Property Office (CIPO) released guidance for examination of diagnostic method claims: Practice Notice:


European alliance of plant breeders fails to halt the March of the NAGOYA protocol
  • Herbert Smith Freehills LLP
  • European Union
  • July 2 2015

The CJEU has rejected two challenges to the EU Regulation implementing the Nagoya Protocol. This piece of international law has changed significantly


Beware the quagmire of personal jurisdiction
  • Proskauer Rose LLP
  • USA
  • July 2 2015

A plaintiff in the District of New Hampshire recently found itself stuck in an unenviable and inescapable jurisdictional hole. Plaintiff Presby


Biosimilar declaratory judgment actions may not be ripe for the taking
  • Fish & Richardson PC
  • USA
  • July 2 2015

In 2014, the Southern District of New York dismissed two biosimilar patent litigation actions on ripeness grounds. Holding that no justiciable case


Rescinding estoppel: the most overlooked means to a broader claim construction
  • Carter DeLuca Farrell & Schmidt LLP
  • USA
  • July 2 2015

The starting point for achieving a broad claim construction is a well written application, the use of non-limiting traversal of adverse patent office


IPR institution can be denied based on petition length or failure to identify related matters
  • Armstrong Teasdale LLP
  • USA
  • July 2 2015

IPR Petitioners often wrestle with determining how much content to put into a petition (and related declarations and exhibits) before considering


Inventive step: how high is the obviousness threshold?
  • Bird & Bird
  • Australia
  • July 2 2015

As part of the long running legal battle in Australia concerning the validity (and infringement) of a series of second generation patents in respect